JP2024156736A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024156736A5 JP2024156736A5 JP2024118592A JP2024118592A JP2024156736A5 JP 2024156736 A5 JP2024156736 A5 JP 2024156736A5 JP 2024118592 A JP2024118592 A JP 2024118592A JP 2024118592 A JP2024118592 A JP 2024118592A JP 2024156736 A5 JP2024156736 A5 JP 2024156736A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- pharmaceutical composition
- act
- grade
- crs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 206010052015 cytokine release syndrome Diseases 0.000 claims 12
- 206010037660 Pyrexia Diseases 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 238000002659 cell therapy Methods 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 5
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 230000000977 initiatory effect Effects 0.000 claims 4
- 230000001988 toxicity Effects 0.000 claims 4
- 231100000419 toxicity Toxicity 0.000 claims 4
- 208000001953 Hypotension Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 206010029350 Neurotoxicity Diseases 0.000 claims 3
- 206010044221 Toxic encephalopathy Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000036543 hypotension Effects 0.000 claims 3
- 230000007135 neurotoxicity Effects 0.000 claims 3
- 231100000228 neurotoxicity Toxicity 0.000 claims 3
- 150000003431 steroids Chemical class 0.000 claims 3
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 claims 2
- 206010021143 Hypoxia Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000007954 hypoxia Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000008177 pharmaceutical agent Substances 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 229960003989 tocilizumab Drugs 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 claims 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 238000011467 adoptive cell therapy Methods 0.000 claims 1
- 230000001754 anti-pyretic effect Effects 0.000 claims 1
- 239000002221 antipyretic Substances 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 229950001565 clazakizumab Drugs 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 229950010006 olokizumab Drugs 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- 229950006348 sarilumab Drugs 0.000 claims 1
- 229960003323 siltuximab Drugs 0.000 claims 1
- 229950006094 sirukumab Drugs 0.000 claims 1
- 230000007675 toxicity by organ Effects 0.000 claims 1
- 231100000155 toxicity by organ Toxicity 0.000 claims 1
- 239000005526 vasoconstrictor agent Substances 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662311906P | 2016-03-22 | 2016-03-22 | |
| US62/311,906 | 2016-03-22 | ||
| US201662417287P | 2016-11-03 | 2016-11-03 | |
| US62/417,287 | 2016-11-03 | ||
| US201662429722P | 2016-12-02 | 2016-12-02 | |
| US62/429,722 | 2016-12-02 | ||
| JP2019500746A JP7048571B2 (ja) | 2016-03-22 | 2017-03-22 | 毒性を予防または改善するための早期介入法 |
| PCT/US2017/023676 WO2017165571A1 (en) | 2016-03-22 | 2017-03-22 | Early intervention methods to prevent or ameliorate toxicity |
| JP2022047991A JP7528143B2 (ja) | 2016-03-22 | 2022-03-24 | 毒性を予防または改善するための早期介入法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022047991A Division JP7528143B2 (ja) | 2016-03-22 | 2022-03-24 | 毒性を予防または改善するための早期介入法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024156736A JP2024156736A (ja) | 2024-11-06 |
| JP2024156736A5 true JP2024156736A5 (enExample) | 2025-01-27 |
Family
ID=58609964
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019500746A Active JP7048571B2 (ja) | 2016-03-22 | 2017-03-22 | 毒性を予防または改善するための早期介入法 |
| JP2022047991A Active JP7528143B2 (ja) | 2016-03-22 | 2022-03-24 | 毒性を予防または改善するための早期介入法 |
| JP2024118592A Pending JP2024156736A (ja) | 2016-03-22 | 2024-07-24 | 毒性を予防または改善するための早期介入法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019500746A Active JP7048571B2 (ja) | 2016-03-22 | 2017-03-22 | 毒性を予防または改善するための早期介入法 |
| JP2022047991A Active JP7528143B2 (ja) | 2016-03-22 | 2022-03-24 | 毒性を予防または改善するための早期介入法 |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US11518814B2 (enExample) |
| EP (3) | EP4015536A1 (enExample) |
| JP (3) | JP7048571B2 (enExample) |
| KR (1) | KR20190021200A (enExample) |
| CN (1) | CN109476743A (enExample) |
| AU (2) | AU2017238218B2 (enExample) |
| BR (1) | BR112018069251A2 (enExample) |
| CA (1) | CA3018588A1 (enExample) |
| ES (1) | ES2907557T3 (enExample) |
| MA (2) | MA44486A (enExample) |
| MX (1) | MX2018011480A (enExample) |
| RU (1) | RU2018136877A (enExample) |
| WO (1) | WO2017165571A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150320799A1 (en) | 2012-12-20 | 2015-11-12 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| SG10202104804PA (en) | 2014-10-20 | 2021-06-29 | Juno Therapeutics Inc | Methods and compositions for dosing in adoptive cell therapy |
| ES2901795T3 (es) | 2015-12-04 | 2022-03-23 | Juno Therapeutics Inc | Métodos y composiciones relacionadas con la toxicidad asociada con la terapia celular |
| JP7048571B2 (ja) | 2016-03-22 | 2022-04-05 | シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） | 毒性を予防または改善するための早期介入法 |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| RU2019120398A (ru) * | 2016-12-03 | 2021-01-12 | Джуно Терапьютикс, Инк. | Способы определения дозировки cart-клеток |
| EP3579870A4 (en) | 2017-02-07 | 2020-12-30 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS |
| CA3053539A1 (en) | 2017-02-27 | 2018-08-30 | Juno Therapeutics, Inc. | Compositions, articles of manufacture and methods related to dosing in cell therapy |
| WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| US11564946B2 (en) | 2017-11-01 | 2023-01-31 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
| WO2019109053A1 (en) * | 2017-12-01 | 2019-06-06 | Juno Therapeutics, Inc. | Methods for dosing and for modulation of genetically engineered cells |
| AU2019209432A1 (en) * | 2018-01-22 | 2020-08-06 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of use for CAR T cells |
| CN111936518A (zh) | 2018-02-06 | 2020-11-13 | 西雅图儿童医院（Dba西雅图儿童研究所） | 对fl-ple标记的肿瘤表现出最佳的t细胞功能的荧光素特异性car |
| BR122023022189A2 (pt) | 2018-02-16 | 2024-02-20 | Incyte Corporation | Usos de inibidores da via de jak1 para o tratamento de distúrbios relacionados a citocinas |
| WO2019165237A1 (en) | 2018-02-23 | 2019-08-29 | Endocyte, Inc. | Sequencing method for car t cell therapy |
| WO2019170845A1 (en) * | 2018-03-09 | 2019-09-12 | Ospedale San Raffaele S.R.L. | Il-1 antagonist and toxicity induced by cell therapy |
| CN111989344A (zh) * | 2018-03-09 | 2020-11-24 | 科济生物医药（上海）有限公司 | 用于治疗肿瘤的方法和组合物 |
| US20210263045A1 (en) * | 2018-04-06 | 2021-08-26 | The Board Of Regents Of The University Of Texas System | Prediction and treatment of immunotherapeutic toxicity |
| WO2021028469A1 (en) * | 2019-08-12 | 2021-02-18 | Sitokine Limited | Compositions and methods for treating cytokine release syndrome and neurotoxicity |
| ES2970382T3 (es) * | 2019-08-14 | 2024-05-28 | Rigel Pharmaceuticals Inc | Método para bloquear o mejorar el síndrome de liberación de citocinas |
| US11045546B1 (en) | 2020-03-30 | 2021-06-29 | Cytodyn Inc. | Methods of treating coronavirus infection |
| US20230366893A1 (en) * | 2020-09-29 | 2023-11-16 | Washington University | Methods to determine risk of neurotoxicity |
| WO2022125670A1 (en) | 2020-12-08 | 2022-06-16 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of vitiligo |
| DK4333840T3 (da) | 2021-05-03 | 2025-11-24 | Incyte Corp | Jak1-vejinhibitorer til behandling af prurigo nodularis |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US265209A (en) | 1882-09-26 | Automatic feeder for perforators | ||
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US4795698A (en) | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
| IN165717B (enExample) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| ATE114507T1 (de) | 1988-12-28 | 1994-12-15 | Stefan Miltenyi | Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien. |
| US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
| EP0557459B1 (en) | 1990-11-13 | 1997-10-22 | Immunex Corporation | Bifunctional selectable fusion genes |
| CA2147466A1 (en) | 1992-10-20 | 1994-04-28 | Just P. J. Brakenhoff | Interleukin-6 receptor antagonists |
| US6080407A (en) * | 1993-05-17 | 2000-06-27 | The Picower Institute For Medical Research | Diagnostic assays for MIF |
| WO1994028143A1 (en) | 1993-05-21 | 1994-12-08 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| DE19608753C1 (de) | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
| WO1997034634A1 (en) | 1996-03-20 | 1997-09-25 | Sloan-Kettering Institute For Cancer Research | Single chain fv constructs of anti-ganglioside gd2 antibodies |
| WO2000014257A1 (en) | 1998-09-04 | 2000-03-16 | Sloan-Kettering Institute For Cancer Research | Fusion receptors specific for prostate-specific membrane antigen and uses thereof |
| AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| WO2001094944A2 (en) | 2000-06-02 | 2001-12-13 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
| EP1334188B1 (en) | 2000-11-07 | 2006-08-30 | City of Hope | Cd19-specific redirected immune cells |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| WO2007147623A2 (en) * | 2006-06-22 | 2007-12-27 | Cellact Pharma Gmbh | A novel target in the treatment of cytokine release syndrome |
| PT2856876T (pt) | 2007-03-30 | 2018-03-28 | Memorial Sloan Kettering Cancer Center | Expressão constitutiva de ligantes co-estimulatórios em linfócitos t adotivamente transferidos |
| EP3338895B1 (en) | 2007-12-07 | 2022-08-10 | Miltenyi Biotec B.V. & Co. KG | Sample processing systems and methods |
| US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
| US20120164718A1 (en) | 2008-05-06 | 2012-06-28 | Innovative Micro Technology | Removable/disposable apparatus for MEMS particle sorting device |
| JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
| PL3006459T3 (pl) | 2008-08-26 | 2022-01-17 | City Of Hope | Sposób i kompozycje dla wzmocnionego działania efektorowego komórek t przeciw guzowi nowotworowemu |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| ES2911246T3 (es) | 2009-11-03 | 2022-05-18 | Hope City | Receptor del factor de crecimiento epidérmico truncado (EGFRT) para selección de células T transducidas |
| CA2810465C (en) * | 2010-09-16 | 2018-10-02 | Baliopharm Ag | Anti-hutnfr1 antibody |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| KR101976882B1 (ko) | 2011-03-23 | 2019-05-09 | 프레드 헛친슨 켄서 리서치 센터 | 세포 면역요법용 방법 및 조성물 |
| US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
| JP6368243B2 (ja) | 2011-11-11 | 2018-08-08 | フレッド ハッチンソン キャンサー リサーチ センター | がんのためのサイクリンａ１に標的化されたｔ細胞免疫療法 |
| JP6850528B2 (ja) | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| RU2665548C2 (ru) | 2012-05-03 | 2018-08-30 | Фред Хатчинсон Кансэр Рисёч Сентер | Способ получения клеток, экспрессирующих т-клеточный рецептор |
| ES2778701T3 (es) * | 2012-07-13 | 2020-08-11 | The Trustees Of The Univ Of Pennsylvania Center For Technology Transfer | Gestión de toxicidad para la actividad antitumoral de CAR |
| PL2884999T3 (pl) | 2012-08-20 | 2021-07-05 | Fred Hutchinson Cancer Research Center | Sposób i kompozycje do immunoterapii komórkowej |
| RU2729401C2 (ru) | 2012-10-02 | 2020-08-06 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | Композиции и способы для иммунотерапии |
| US9405601B2 (en) | 2012-12-20 | 2016-08-02 | Mitsubishi Electric Corporation | In-vehicle apparatus and program |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
| IL303543A (en) * | 2015-02-18 | 2023-08-01 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| WO2017035362A1 (en) * | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses |
| US11747346B2 (en) | 2015-09-03 | 2023-09-05 | Novartis Ag | Biomarkers predictive of cytokine release syndrome |
| JP7048571B2 (ja) | 2016-03-22 | 2022-04-05 | シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） | 毒性を予防または改善するための早期介入法 |
| CN120285179A (zh) | 2016-07-15 | 2025-07-11 | 诺华股份有限公司 | 使用与激酶抑制剂组合的嵌合抗原受体治疗和预防细胞因子释放综合征 |
-
2017
- 2017-03-22 JP JP2019500746A patent/JP7048571B2/ja active Active
- 2017-03-22 KR KR1020187030514A patent/KR20190021200A/ko not_active Withdrawn
- 2017-03-22 BR BR112018069251A patent/BR112018069251A2/pt not_active IP Right Cessation
- 2017-03-22 RU RU2018136877A patent/RU2018136877A/ru not_active Application Discontinuation
- 2017-03-22 MA MA044486A patent/MA44486A/fr unknown
- 2017-03-22 EP EP21207779.6A patent/EP4015536A1/en active Pending
- 2017-03-22 EP EP24221056.5A patent/EP4545143A3/en active Pending
- 2017-03-22 MA MA71266A patent/MA71266A/fr unknown
- 2017-03-22 MX MX2018011480A patent/MX2018011480A/es unknown
- 2017-03-22 AU AU2017238218A patent/AU2017238218B2/en active Active
- 2017-03-22 US US16/087,488 patent/US11518814B2/en active Active
- 2017-03-22 CA CA3018588A patent/CA3018588A1/en active Pending
- 2017-03-22 WO PCT/US2017/023676 patent/WO2017165571A1/en not_active Ceased
- 2017-03-22 ES ES17719044T patent/ES2907557T3/es active Active
- 2017-03-22 CN CN201780031706.6A patent/CN109476743A/zh active Pending
- 2017-03-22 EP EP17719044.4A patent/EP3433276B1/en not_active Revoked
-
2022
- 2022-03-24 JP JP2022047991A patent/JP7528143B2/ja active Active
- 2022-12-02 US US18/061,196 patent/US11760804B2/en active Active
- 2022-12-05 US US18/061,939 patent/US20230212298A1/en active Pending
-
2023
- 2023-06-06 US US18/329,987 patent/US12098208B2/en active Active
-
2024
- 2024-07-24 AU AU2024205049A patent/AU2024205049A1/en active Pending
- 2024-07-24 JP JP2024118592A patent/JP2024156736A/ja active Pending
- 2024-09-09 US US18/828,243 patent/US20240425608A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024156736A5 (enExample) | ||
| CN102770455B (zh) | 用于体内扩增调节性t细胞的方法 | |
| RU2018136877A (ru) | Способы раннего вмешательства для профилактики или улучшения состояния токсичности | |
| Xiao et al. | The IL-2/Anti-IL-2 complex attenuates cardiac ischaemia-reperfusion injury through expansion of regulatory T cells | |
| FI3886875T3 (fi) | Adoptiivista soluterapiaa käyttäviä hoitomenetelmiä | |
| JP2022532490A (ja) | 癌の治療における有効性の増強のためのｐｄ－１阻害剤とｌａｇ－３阻害剤の組み合わせ | |
| van de Donk et al. | Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies | |
| CN118593691A (zh) | 施用嵌合抗原受体免疫疗法的方法 | |
| JPWO2020113194A5 (enExample) | ||
| JPWO2020250915A5 (enExample) | ||
| WO2020243603A1 (en) | Dosing of bispecific t cell engager | |
| JPWO2019213184A5 (enExample) | ||
| Miyata et al. | Rebamipide enemas–new effective treatment for patients with corticosteroid dependent or resistant ulcerative colitis | |
| JPWO2022240688A5 (enExample) | ||
| WO2024192033A1 (en) | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating melanoma | |
| Stakiw et al. | A Phase II, Open-label study of an accelerated infusion rate of daratumumab in patients with relapsed and refractory multiple myeloma | |
| WO2022126869A1 (zh) | 孕激素在治疗细胞因子释放综合征中的应用 | |
| JPWO2021035054A5 (enExample) | ||
| JPWO2021092056A5 (enExample) | ||
| EP4319815A1 (en) | Dosing of bispecific t cell engager | |
| AU2017322414A1 (en) | Compositions and methods of treating cancer | |
| JPWO2020227177A5 (enExample) | ||
| Watson et al. | BCMA-targeted therapies for multiple myeloma: strategies to maximize efficacy and minimize adverse events | |
| JPWO2021207689A5 (enExample) | ||
| US20250290154A1 (en) | Predictive markers for immunotherapy |